Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Organigram agrees to acquire Aurora Cannabis for CAD 7.80 per share

By Public Technologies
  • Organigram will acquire Aurora Cannabis for CAD 7.80 per share, valuing the transaction at approximately CAD 561 million on a fully diluted basis.
  • The price represents a 93% premium to the August 10, 2026 closing price and 21% above Curaleaf's competing bid.
  • Shareholders can elect cash, Organigram shares or a combination, subject to proration.
  • The combination targets more than CAD 50 million in synergies across its Canadian and international operations.
  • Completion is expected in January 2027, subject to shareholder, regulatory and court approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurora Cannabis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611030916BIZWIRE_USPR_____20261103_BW746636) on November 03, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.